CLCN1: A Drug Target / Disease Biomarker (G1180)

Target Name: CLCN1

NCBI ID: G1180

CLCN1

CLCN1: A Drug Target / Disease Biomarker

CLCN1, also known as CD11b, is a protein that is expressed in the placenta, bone marrow, and other tissues of the body. It is a type of integrin, which is a protein that is found on the surface of many different cell types. Integrins are important for cell-cell adhesion, and they play a role in the development and maintenance of tissues such as the placenta and the bone marrow.

Recent studies have shown that CLCN1 may have a number of different functions in the body. For example, it has been shown to be involved in the development and maintenance of the erythropoietic marrow, which is the tissue that produces red blood cells in the body. CLCN1 has also been shown to play a role in the development and maintenance of the endometrium, which is the tissue that lines the uterus and facilitates menstruation.

Another function that has been suggested for CLCN1 is its potential as a drug target. Integrins are often targeted by drugs because they are involved in cell-cell adhesion, and drugs that can inhibit this interaction between cells may be effective in treating a variety of diseases. CLCN1 is thought to be involved in many of these processes, and so it may be a useful target for researchers to study.

There are currently several drugs that are being developed to target CLCN1, and these drugs have the potential to treat a variety of different diseases. For example, one drug being developed to treat lung cancer is called CLCN1-targeted because it is designed to target CLCN1 specifically. Another drug being developed to treat skin cancer is called CLCN1 inhibitor because it is designed to inhibit the activity of CLCN1.

Another potential application of CLCN1 as a drug target is its role in the development and maintenance of certain diseases. For example, CLCN1 has been shown to be involved in the development of certain types of cancer, such as leukemia and lymphoma. Drugs that can inhibit the activity of CLCN1 in these processes may be effective in treating these diseases.

In addition to its potential as a drug target, CLCN1 has also been shown to have potential as a biomarker. Integrins are often expressed in a variety of different tissues and have been shown to be involved in the development and maintenance of many different diseases. CLCN1 is one of these integrins, and so it may be a useful biomarker for certain types of diseases.

For example, CLCN1 has been shown to be involved in the development and maintenance of certain types of cancer, such as breast cancer. In these cases, the expression of CLCN1 may be an indicator of the risk of cancer and the potential for treatment. Drugs that can inhibit the activity of CLCN1 in these processes may be effective in detecting and treating cancer at an early stage.

Overall, CLCN1 is a protein that is involved in a variety of different processes in the body. Its potential as a drug target and biomarker make it an attractive target for researchers to study. Further research is needed to fully understand the role of CLCN1 in the body and its potential as a drug and biomarker.

Protein Name: Chloride Voltage-gated Channel 1

Functions: Voltage-gated chloride channel (PubMed:8112288, PubMed:9122265, PubMed:12456816). Plays an important role in membrane repolarization in skeletal muscle cells after muscle contraction. The CLC channel family contains both chloride channels and proton-coupled anion transporters that exchange chloride or another anion for protons (Probable). The absence of conserved gating glutamate residues is typical for family members that function as channels (Probable)

The "CLCN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLCN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets